Previous studies have reported several sensitive mutations among the uncommon mutations in EGFR, including G719X, S768I, and L861Q, which have preliminarily shown responsiveness to both afatinib and osimertinib, with better brain infiltration in NSCLC patients.6, 8. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.